11:49 AM EST - Therapeutics Inc. : Provided financial results for the year ended December 31, 2016. At year’s end, Trillium had cash of $50.5 million. For the year ended December 31, 2016, the company used $22.9 million of cash for operations; $9.6 million for the acquisition of Fluorinov Pharma Inc; and used $3.0 million for capital purchases related to its new office and laboratory facility. Net loss for the year ended December 31, 2016 of $31.7 million was higher than the loss of $14.7 million for the year ended December 31, 2015. Therapeutics Inc.
shares T.TRIL are trading up $0.11 at $8.16.
